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ABSTRACT
Objective To assess the risk of venous thrombosis in
current users of different types of hormonal
contraception,focusingonregimen,oestrogendose,type
of progestogen, and route of administration.
Design National cohort study.
Setting Denmark, 1995-2005.
ParticipantsDanishwomenaged15-49withnohistoryof
cardiovascular or malignant disease.
Main outcome measures Adjusted rate ratios for all first
time deep venous thrombosis, portal thrombosis,
thrombosis of caval vein, thrombosis of renal vein,
unspecified deep vein thrombosis, and pulmonary
embolism during the study period.
Results 10.4 million woman years were recorded, 3.3
million woman years in receipt of oral contraceptives. In
total, 4213 venous thrombotic events were observed,
2045 in current users of oral contraceptives. The overall
absolute risk of venous thrombosis per 10000 woman
years in non-users of oral contraceptives was 3.01 and in
current users was 6.29. Compared with non-users of
combined oral contraceptives the rate ratio of venous
thrombembolism in current users decreased with
duration of use (<1 year 4.17, 95% confidence interval
3.73 to 4.66, 1-4 years 2.98, 2.73 to 3.26, and >4 years
2.76, 2.53 to 3.02; P<0.001) and with decreasing dose of
oestrogen. Compared with oral contraceptives containing
levonorgestrel and with the same dose of oestrogen and
length of use, the rate ratio for oral contraceptives with
norethisteronewas0.98(0.71to1.37),withnorgestimate
1.19 (0.96 to 1.47), with desogestrel 1.82 (1.49 to 2.22),
with gestodene 1.86 (1.59 to 2.18), with drospirenone
1.64 (1.27 to 2.10), and with cyproterone 1.88 (1.47 to
2.42). Compared with non-users of oral contraceptives,
the rate ratio for venous thromboembolism in users of
progestogen only oral contraceptives with levonorgestrel
or norethisterone was 0.59 (0.33 to 1.03) or with 75 μg
desogestrel was 1.12 (0.36 to 3.49), and for hormone
releasing intrauterine devices was 0.90 (0.64 to 1.26).
ConclusionTheriskofvenousthrombosisincurrentusers
of combined oral contraceptives decreases with duration
of useanddecreasing oestrogendose.Forthe samedose
of oestrogen and the same length of use, oral
contraceptives with desogestrel, gestodene, or
drospirenone were associated with a significantly higher
risk of venous thrombosis than oral contraceptives with
levonorgestrel. Progestogen only pills and hormone
releasing intrauterine devices were not associated with
any increased risk of venous thrombosis.
INTRODUCTION
Studieshaveshownanincreasedriskofvenousthrom-
bosis with use of combined oral contraceptives.
1-14
These studies have generally found a higher risk dur-
ing the first year of use and with oral contraceptives
containing desogestrel or gestodene rather than
levonorgestrel.
1-68912
With the shift from combined pills containing 50 μg
ethinylestradiol (oestrogen) to low dose pills contain-
ing30-40μg,adecreaseintheriskofvenousthrombo-
sis would be expected. Results have, however, been
conflicting,
1215 and evidence of a further decrease in
risk associated with a reduction to 20 μg oestrogen is
lacking.
12 In addition, evidence is sparse on the risk of
venous thromboembolism with oral contraceptives
containingthenewprogestogendrospirenone,proges-
togen only pills with 75 µg desogestrel, and hormone
releasing intrauterine devices.
Weassessedtheriskofvenousthromboembolismin
currentusersofdifferenttypesofhormonalcontracep-
tion, focusing on duration of use, regimen (combined
oral contraceptives versusprogestogen only pills), and
the effect of oestrogen dose, type of progestogen, and
route of administration.
METHODS
Thisstudywasdesignedasacohortstudy,withlinkage
between four national Danish registries for prescrip-
tions, education, and health. The National Registry of
Medicinal Products Statistics has recorded all
redeemed prescriptions on Danish citizens since 1994
according to specific Anatomical Therapeutic Chemi-
cal(ATC)codesandtheamountofdrugsprescribed,in
defined daily doses. Since 1977 the National Registry
of Patients has collected discharge diagnoses and sur-
gicalcodesfromallDanishhospitals.Thisregistryalso
includes births and abortions. Diagnoses are classified
accordingtotheinternationalclassificationofdiseases;
before1994usingtheeighthrevisionandthereafterthe
10th revision. Statistics of Denmark include updated
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ongoingorcompletededucationofallDanishcitizens.
The Central Person Registry includes a 10 digit perso-
nal identification number of all Danish citizens, given
at birth or immigration, and information on address
and vital status that is updated daily. The personal
identification number is a unique personal identifier
recorded in all public registries, thus allowing linkage
between these registries.
Study population
Danish women aged 15-49 from 1 January 1995 to 31
December 2005 were identified in the Central Person
Registry.
In the National Registry of Patients we identified
women (n=14749) with malignant disease (ICD 8
codes 153, 154, 183, 184, and 200-206, or ICD 10
codes DC81-85, DC88, and DC90-96) and those
(n=20128) with a cardiovascular event (ICD 8 codes
430, 431, 433, 434, 436, 450, 451.00/08/99, 452, and
453.02,orICD10codesDI21-26,DI60-64,andDI80-
82) before the study period (1977-94). These 34877
women were excluded because of their increased risk
for venous thrombosis, decreased probability of being
usersofcombinedoralcontraceptives,andbecausewe
aimed to assess the risk for a first ever thrombotic
event. New cases of cancer or cardiovascular diseases
during the study period were censored at the date of
diagnosis. Women who emigrated were censored at
the time they left the country.
From the abortion and birth registry we identified
women who were pregnant during the study period,
by identifying those who had delivered (DO600-
DO849) and those who had a miscarriage (DO021
and DO03), induced abortion (DO040-DO059), or
ectopic pregnancy (DO000-DO009). Algorithms for
the length of pregnancy in each case were generated
from the record of the gestational age, and these
women were excluded from the study during preg-
nancy and 12 weeks after delivery or four weeks after
an abortion or ectopic pregnancy. Thus 805464
women were excluded from the study population for
a period of 460465 pregnancy years. The study popu-
lation therefore comprised all non-pregnant women
with no previous cancer or cardiovascular diseases.
End points
Ourendpointswerefirsttimedeepvenousthrombosis
(ICD 10 codes DI801, DI802, and DI803), portal
thrombosis (DI81), thrombosis of caval vein (DI822),
thrombosis of renal vein (DI823), unspecified deep
vein thrombosis (DI828 and DI829), and pulmonary
embolism (DI26) during the study period.
We have previously validated diagnoses of venous
thromboembolism in the National Registryof Patients
(1994-8) and found about 10% uncertain.
12 In the
remaining included women with diagnoses, 97% had
been examined by venography or ultrasonography
and 94% had received anticoagulation therapy. Of
the 3% who were not examined by venography or
ultrasonography, 2% received anticoagulation
therapy. Thus the diagnosis was uncertain in less than
1% of participants.
Data on use of hormonal contraception
FromtheNationalRegistryofMedicinalProductsSta-
tistics we obtained data onuse of hormonal contracep-
tives among Danish women aged 15-49 during the
study period.
Current use of hormonal contraception was defined
as having a valid prescription at time of admission to
hospital according to prescribed defined daily doses.
Previous use was defined as any previous recorded
use during the study period, and never use as no
recorded prescription for hormonal contraception
during the study period. Length of use was defined as
the sum of valid prescriptions, with periods of non-use
subtracted if they occurred between periods of use.
Hormone releasing intrauterine devices were
assumedtobeusedforanaverageofthreeyears,unless
a new device was prescribed within a six year period
fromthelatestprescription.Inthatcasethewomanwas
assumed to have had an intrauterine device without
interruption. If oral contraception was prescribed
before the three years expired, the device was consid-
ered to have been removed at the time the oral contra-
ceptive was prescribed.
Hormonalcontraceptionwascategorisedaccordingto
time of usage (current, previous, or never), regimen
(combined oral contraceptives, progestogen only pills,
or hormone releasing intrauterine device), oestrogen
dose (50 μg, 30-40 μg, or 20 μg), type of progestogen
(norethisterone, levonorgestrel, norgestimate, deso-
gestrel, gestodene, drospirenone, or cyproterone), and
length of use of combined oral contraceptives in current
users (<1 year, 1-4 years, or >4 years). Progestogen only
pills were subdivided into those containing 30 µgl e v o -
norgestrelor350µgnorethisteroneandthosecontaining
75 µg desogestrel.
We chose non-users of oral contraceptives (never
usersplusformerusers)asourreferencegroupbecause
never users are an increasingly selected group of
women, and some who were categorised as never
usersinourstudywindowmighthaveusedoralcontra-
ceptives before 1995.
Confounders
FromtheNationalRegistryofMedicinalProductsSta-
tistics we also obtained information on redeemed
drugs for diabetes (ATC A10), heart disease (ATC
C01), antihypertension (ATC C02), diuresis (ATC
C03), β blockade (ATC C07), calcium antagonism
(ATC C08), the renin-angiotensin system (ATC
C09), and serum lipid lowering (ATC C10).
Informationaboutschoolingandeducationwaspro-
vided by Statistics Denmark. Educational level was
categorisedintofourgroups:primaryschoolonly,sec-
ondaryschoolonly,anyschoolwiththreeorfouryears
offurthereducation,andsecondaryschoolwithfiveor
six years of further education.
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DatawereanalysedusingPoissonregression.Thedata
consisted of time at risk (woman years) and number of
venous thrombotic events for each combination of
hormonal contraception, length of use, age band, and
educationallevel.Agewasusedasthetimescaleinana-
lyses and divided into five year bands, assuming a lin-
ear trend in risk of venous thromboembolism within
each band. Confounders were retained in the multi-
variate analysis if they changed the estimates by more
than 5%.
Absolute crude risk estimates and adjusted rate
ratios, with 95% confidence intervals, were calculated
for specific combinations of oestrogen dose, progesto-
gen type, and length of use. In addition we calculated
the influence of specific types of progestogen after
adjustment for length of use.
RESULTS
The analysis included 3.4 million woman years of cur-
rent use, 2.3 million woman years of former use, 4.8
million woman years of never use, or a total of 10.4
million woman years of observation (table 1). A total
of 4213 first time venous thrombotic events were
recorded during the study period and of these 2045
were among current users of hormonal contraception.
The venous thrombotic events included deep vein leg
thrombosis (61.8%), pulmonary embolism (26.2%),
femoral vein thrombosis (4.7%), portal thrombosis
(1.2%), caval or renal thrombosis (0.8%), and unspeci-
fied deep vein thrombosis (5.4%).
Drugsagainstdiabetes,heartdiseases,hypertension,
and hyperlipidaemia influenced the risk estimates of
oral contraceptives by less than 5%, and were conse-
quently excluded. Age, calendar year, and education
were all significant confounders and were included in
theanalysis.Therewasnointeractionbetweenageand
the calculated rate ratios.
Figure 1 shows the use of different oral contracep-
tives by age. Generally, young women more often
used newer oral contraceptives than older women,
who more often used hormone releasing intrauterine
devices.Atthesametime,theproportionofshortterm
users was higher among young women.
The incidence of venous thromboembolism
increased with age, from 1.84 per 10000 woman
years in women aged 15-19 to 6.59 per 10000
woman years in women aged 45-49 (table 1). The inci-
dence also increased during the 11 years of the study
period, on average by 1.05 (95% confidence interval
Table 1 |Crude incidence rates and adjusted rate ratios of venous thrombosis in women using different types of hormonal contraception
Characteristics Woman years % of woman years
Noofwomenwithvenous
thrombosis
Rate per 10 000
woman years
Adjusted rate ratio
(95% CI)
Age group
15-19 1 359 821 13.0 250 1.84 0.39 (0.33 to 0.45)*
20-24 1 491 764 14.3 444 2.98 0.62 (0.54 to 0.70)*
25-29 1 491 959 14.3 537 3.60 0.86 (0.76 to 0.96)*
30-34 1 587 896 15.2 598 3.77 Reference
35-39 1 628 852 15.6 685 4.21 1.18 (1.05 to 1.32)*
40-44 1 518 172 14.5 797 5.25 1.57 (1.41 to 1.74)*
45-49 1 368 909 13.1 902 6.59 2.09 (1.88 to 2.32)*
Total 10 447 373 100.0 4213 4.03 —
Previous use
Never 4 813 053 46.1 1467 3.05 Reference
Former 2 278 576 21.8 667 2.93 1.08 (0.98 to 1.18)†
Current use
Non-use (never or former use of oral contraceptives) 7 194 242 67.9 2168 3.01 Reference
Current use of oral contraceptives 3 253 131 31.1 2045 6.29 2.83 (2.65 to 3.01)†
Use of combined pill:
<1 year 684 061 21.6 443 6.48 4.17 (3.73 to 4.66)†
1-4 years 1 449 000 45.8 787 5.43 2.98 (2.73 to 3.26)†
>4 years 1 031 953 32.6 793 7.68 2.76 (2.53 to 3.02)†
Oral contraceptives with 50 μg oestrogen 82 902 2.5 65 7.84 2.67 (2.09 to 3.42)†
Oral contraceptives with 20-40 μg oestrogen and:
Levonorgestrel 367 408 10.9 201 5.47 2.02 (1.75 to 2.34)†
Desogestrel or gestodene 2 008 262 59.8 1370 6.82 3.55 (3.30 to 3.83)†
Drospirenone 131 541 3.9 103 7.83 4.00 (3.26 to 4.91)†
Progestogen only:
Levonorgestrel 30 μg or norethisterone 350 μg 65 820 0.6 12 1.82 0.59 (0.33 to 1.04)†
Desogestrel 75 μg 9044 0.1 3 3.32 1.10 (0.35 to 3.41)†
Hormone releasing intrauterine device 101 351 1.0 34 3.35 0.89 (0.64 to 1.26)
*Adjusted for current use of oral contraceptives, calendar year, and educational level.
†Adjusted for age, calendar year, and educational level.
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venous thromboembolism increased with decreasing
education. Using the least educated women (primary
school only) as the reference group, the rate ratios of
venous thromboembolism for those with secondary
school education only was 0.52 (0.46 to 0.59), with
any schooling and three or four years of further
education was 0.58 (0.54 to 0.63), and with secondary
school education with five or six years of further edu-
cation was 0.43 (0.39 to 0.47).
The crude incidence of venous thromboembolism
among non-users (never or former use) of hormonal
contraceptives was 3.01 per 10000 woman years, and
among current users of oral contraceptives was on
average 6.29 per 10000 woman years (table 1).
Combined oral contraceptives
The risk among women using combined oral contra-
ceptives decreased with duration of use, from an
adjusted rate ratio of 4.17 (95% confidence interval
3.73 to 4.66) during the first year of use to 2.76 (2.53
to 3.02) after more than four years of use (table 1).
The risk among current users of combined oral con-
traceptives was also influenced by oestrogen dose and
type of progestogen. Table 2 shows the adjusted rate
ratios for specific combinations of these three vari-
ables.
For a given progestogen type and after adjustment
for length of use, the risk of venous thromboembolism
decreased with decreasing dose of oestrogen (table 3).
A reduction in oestrogen dose from 50 µg to 30-40 µg
in oral contraceptives containing levonorgestrel
reduced the risk by 17% (NS), and for oral contracep-
tives containing norethisterone by 32% (NS). Further-
more, a reduction in oestrogen dose from 30-40 µgt o
20 µgfor oral contraceptives containing desogestrelor
gestodene reduced the risk of venous thromboembo-
lism by 18% (7% to 27%).
Compared with current users of oral contraceptives
containing levonorgestrel, using the same dose of oes-
trogenandafteradjustmentfordurationofuse,therate
ratios of venous thromboembolism in women using
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Table 2 |Observation years, number of venous thromboembolism events, crude incidence rate per 10 000 user years, and adjusted* rate ratios (95%
confidence intervals) of venous thromboembolism in current users of combined oral contraceptives according to oestrogen dose, progestogen type, and
length of use, with non-users of oral contraceptives as reference group
Variables
Progestogen
Norethisterone Levonorgestrel Norgestimate Desogestrel Gestodene Drospirenone Cyproterone
Woman years 157 962 411 099 329 463 676 105 1 332 157 131 541 126 687
Thrombotic event 71 238 151 442 928 103 90
Crude rate 4.5 5.8 4.6 6.5 7.0 7.8 7.1
Rate ratio*
Oestrogen dose and duration of use
Oestrogen 50 μg:
<1 year 2.89 (1.37 to 6.07) 3.06 (1.53 to 6.14) —— —— —
1-4 years 2.35 (1.30 to 4.26) 2.00 (1.11 to 3.63) —— —— —
>4 years 4.05 (2.18 to 7.54) 2.78 (1.75 to 4.43) —— —— —
Oestrogen 30-40 μg:
<1 year 2.81 (1.66 to 4.77) 1.91 (1.31 to 2.79) 3.37 (2.38 to 4.76) 5.58 (4.13 to 7.55) 4.38 (3.65 to 5.24) 7.90 (5.65 to 11.0) 6.68 (4.50 to 9.94)
1-4 years 1.76 (1.12 to 2.77) 2.23 (1.78 to 2.78) 2.27 (1.74 to 2.96) 3.48 (2.74 to 4.42) 3.85 (3.39 to 4.36) 2.68 (1.86 to 3.86) 3.24 (2.28 to 4.61)
>4 years 1.55 (0.83 to 2.89) 1.91 (1.55 to 2.36) 2.20 (1.70 to 2.85) 3.19 (2.53 to 4.02) 3.34 (2.95 to 3.78) 3.26 (2.35 to 4.54) 3.37 (2.38 to 4.76)
Oestrogen 20 μg:
<1 year —— — 4.89 (3.83 to 6.23) 4.43 (3.25 to 6.04) ——
1-4 years —— — 2.83 (2.29 to 3.49) 3.27 (2.61 to 4.10) ——
>4 years —— — 2.69 (2.17 to 3.35) 2.79 (2.15 to 3.63) ——
*All estimates adjusted for age, calendar year, and education and with non-users of oral contraceptives as reference group.
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(0.71 to 1.37), norgestimate 1.19 (0.96 to 1.47), deso-
gestrel 1.82 (1.49 to 2.22), gestodene 1.86 (1.59 to
2.18), drospirenone 1.64 (1.27 to 2.10), and cyproter-
one 1.88 (1.47 to 2.42; table 3).
Progestogen only pills
Progestogenonlypillscontaininglevonorgestrel30μg
or norethisterone 350 μg, as well as desogestrel 75 μg
did not confer any increased risk of venous throm-
boembolism when compared with non-users of oral
contraceptives, and women using hormone releasing
intrauterine devices had an adjusted rate ratio for
venous thromboembolism of 0.89 (0.64 to 1.26;
table 1).
DISCUSSION
The risk of venous thromboembolism in current users
of combined oral contraceptives decreases with dura-
tion of use and decreasing oestrogen dose. For the
same dose of oestrogen and the same length of use,
oral contraceptives containing desogestrel, gestodene,
or drospirenone were associated with a higher risk of
venous thromboembolism than oral contraceptives
containing levonorgestrel. Progestogen only pills and
hormone releasing intrauterine devices did not confer
any increased risk of venous thromboembolism.
The extent of an overall risk estimate of venous
thromboembolism in current users of oral contracep-
tives depends on several factors. Exclusion of women
with previous thrombosis and cancer from the refer-
ence group would increase the overall risk estimate
because of the decreased risk in the reference group.
The estimate would also be increased by the inclusion
ofrelatively morenewusers orshortterm usersoforal
contraceptives,orifmanywomenwereusingoralcon-
traceptives that contained desogestrel, gestodene, or
drospirenone compared with those containing levo-
norgestrel. The inclusion of pregnant women in the
reference group or women using progestogen only
pills in the oral contraceptives group would, however,
decrease the overall estimate for oral contraceptives.
The diagnosis of venous thromboembolism has
improvedovertimebecauseofbetterdiagnosticequip-
ment. Therefore more venous thromboses would be
diagnosed today than previously. As a consequence,
newer absolute risk estimates would be expected to
be higher than older estimates. The relative risk esti-
mates, however, are less sensitive to this time trend,
and we controlled for this in the study by including
calendar year in the multivariate analyses.
These methodological circumstances may explain
the apparently contradictory results from other stu-
dies. As we included non-users of oral contraceptives
as our reference population, effectively excluded
women with a history of cancer or cardiovascular
events, had less than one third long term users, and
most of the women were users of low dose oral contra-
ceptives, our overall risk estimates for oral contracep-
tives containing levonorgestrel, desogestrel, or
gestodene are slightly lower than in previous studies
andlowerthantheestimatesinourpreviousstudycov-
ering 1994-8.
12
Our results confirm that the risk in users of com-
bined oral contraceptives depends on the dose of oes-
trogen, type of progestogen, and length of use.
Reducing the dose of oestrogen from 50 μg to 30-40
μg non-significantly reduced the risk of venous throm-
boembolism by 17-32%. Reducing the dose from 30-
40μgto20μginusersoforalcontraceptivescontaining
desogestrel or gestodene significantly reduced the risk
ofvenousthromboembolism by18%(95% confidence
interval 7% to 27%), after adjustment for duration of
use of oral contraceptives. Without this adjustment
the association was confounded and not significant.
Together with the lack of power this may explain
why few studies have been able to show this dose-
responserelation.Thedose-responserelationbetween
oral contraceptive use and venous thromboembolism
strengthenstheevidencethatthestatisticalassociations
reflect a causal relation.
Thehigherriskofvenousthromboembolisminusers
of oral contraceptives containing desogestrel or gesto-
dene compared with those containing levonorgestrel is
Table 3 |Adjusted rate ratios (95% confidence intervals) of venous thromboembolism in current users of combined oral contraceptives according to
oestrogen dose and progestogen type after adjustment for length of use
Variables
Progestogen
Norethisterone Levonorgestrel Norgestimate Desogestrel Gestodene Drospirenone Cyproterone
Oestrogen 50 µg: 1.44 (0.97 to 2.14) 1.20 (0.85 to 1.71) —— —— —
Woman years 39 211 43 691 —— —— —
Venous
thrombembolism
28 37 —— —— —
Oestrogen 30-40 µg: 0.98 (0.71 to 1.37) 1 (reference) 1.19 (0.96 to 1.47) 1.82 (1.49 to 2.22) 1.86 (1.59 to 2.18) 1.64 (1.27 to 2.10) 1.88 (1.47 to 2.42)
Woman years 118 751 367 408 329 463 233 883 1 012 977 131 541 126 687
Venous
thrombembolism
43 201 151 191 744 103 90
Oestrogen 20 µg: —— — 1.51 (1.25 to 1.82) 1.51 (1.22 to 1.86) ——
Woman years —— — 442 223 319 180 ——
Venous
thrombembolism
—— — 251 184 ——
Rate ratios adjusted for age, calendar year, education, and length of use.
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16-912 although not
all
713 (table 4). According to our data, oral contracep-
tives with norgestimate were associated with about the
same risk of venous thromboembolism as oral contra-
ceptives with levonorgestrel. One study found an abso-
lute risk of 4.2 (95% confidence interval 2.9 to 5.8) per
10000womanyearsinusersoforalcontraceptiveswith
norgestimate,
16 results in line with our 4.6 per 10000
woman years. Our estimate was based on 151 venous
thromboticeventsandishigherthantheestimateinour
previous study, based on 18 venous thrombotic events
for this specific group.
12
Studies have shown a threefold increased risk of
venous thromboembolism in women using oral con-
traceptives that contain cyproterone compared with
non-users,
10-12 results similar to ours.
Three studies have been identified that assessed the
risk of venous thromboembolism in users of oral con-
traceptives containing drospirenone.
131417 The Eur-
opean active surveillance study found 9.1 venous
thrombotic events per 10000 user years (26 events)
in women using oral contraceptives that contained
drospirenone compared with 8.0 per 10000 woman
years (25 events) in those using oral contraceptives
that contained levonorgestrel, and 2.3 per 10000
woman years in non-pregnant non-users (five
events).
13 A case only study showed a risk of venous
thromboembolism in new users of drospirenone of
13.7 per 10000 user years.
17 Another study showed a
similar incidence, of 13 per 10000 drospirenone years
in new users compared with 14 per 10000 user years
for other oral contraceptives, although the types were
not given in the paper.
14
In users of oral contraceptives containing drospire-
none we found an incidence of venousthromboembo-
lism of 7.9 per 10000 woman years and an adjusted
rate ratio of 1.64 (1.27 to 2.10) when compared with
oral contraceptives containing levonorgestrel, and of
4.00 (3.26 to 4.91) when compared with non-users of
oral contraceptives. These estimates were based on
103 venous thrombotic events in users of oral contra-
ceptives with drospirenone. The four times increased
risk of venous thromboembolism compared with non-
users is in accordance with the surveillance study.
13
The higher risk of venous thromboembolism when
compared with users of oral contraceptives containing
levonorgestrelisanewfinding.Thereasonforthisrate
ratio was primarily a lower risk in users of oral contra-
ceptives containing levonorgestrel in our study com-
pared with the same estimates in the surveillance
study.
13 Before general clinical recommendations are
possible this finding should be confirmed in other stu-
dies, and the risk of arterial thrombosis assessed for
oral contraceptives that contain drospirenone. How-
ever, the risk estimate was of the same magnitude as
fororalcontraceptivescontainingdesogestrelorgesto-
dene with the same dose of oestrogen and same length
ofuse, resultsin accordancewithtwo otherstudies.
1314
Finally, the lack of increased risk of venous throm-
bosis by use of progestogen only pills is in line with
previous findings,
12 although the statistical power to
detect small differences was not present owing to the
relatively small number of users of these products.
Thereducedriskofvenousthrombosiswithincreas-
ing length of education could be attributed to the
higher prevalence of obese women with short rather
than long education.
Strengths and limitations of the study
The registry linkage design of this study had some
advantages and some limitations. One strength is the
high external validity, as we included all Danish
women aged 15-49 who fulfilled the inclusion criteria.
Because of the establishment of the National Registry
of Patients in 1977 we were also able to define a popu-
lationwithonlyfirstevervenousthromboembolismin
non-pregnant women.
Table 4 |Studies on oral contraception and venous thromboembolism. Risk estimates are in current users of oral
contraceptives compared with non-users or never users unless stated otherwise
Study
Period of data
sampling
No with venous
thromboembolism
Rate ratio (95% CI) for combined oral contraceptives
Pill with
levonorgestrel
Pill with desogestrel
or gestodene
Pill with
drospirenone
Blomenkamp
1 1988-92 126 3.8 (1.7 to 8.4) 8.7 (3.9 to 19.3) —
WHO
3 1989-93 433 3.6 (1.4 to 7.9) 7.4 (4.2 to 12.9) —
Jick
2 1991-4 80 Reference 1.8 (1.0 to 3.2) —
Spitzer
4 1991-5 471 3.2 (2.3 to 4.3) 4.8 (3.4 to 6.7) —
Lewis
7 1993-5 502 2.9 (1.9 to 4.2) 2.3 (1.5 to 3.5) —
Farmer
5 1991-5 85 3.1* (2.1 to 4.5) 5.0‡ (3.7 to 6.5) —
Todd
8 1992-7 99 Reference 1.4 (0.7 to 2.8) —
Bloemenkamp
6 1994-8 185 3.7 (1.9 to 7.2) 7.0 (NA) —
Lidegaard
12 1994-8 987 2.9 (2.2 to 3.8) 4.0 (3.2 to 4.9) —
Dinger
13 2000-4 118 Reference 1.3 (0.8 to 2.0)† 1.0 (0.6 to 1.8)
Seeger
14 2001-4 57 Reference Reference 1.0 (0.2 to 18.6)
Lidegaard (current study) 1995 4213 2.0 (1.8 to 2.3) 3.6 (3.3 to 3.8) 4.0 (3.3 to 4.9)
WHO=World Health Organization; NA=not available.
*Incidence per 10 000 woman years.
†Our calculation based on data in publication.
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tion registry providedprecise data on use of hormonal
contraception, with detailed information about the
specific product and the length of use. The national
approach ensured a relatively high statistical power
by including 4213 venous thrombotic events. Conse-
quently we were able to assess the risk for specific sub-
types of oral contraceptives and to consider separately
theimportanceofoestrogendose,typeofprogestogen,
and length of use in the risk of venous thrombosis.
Finally, the cohort design allowed the calculation of
absolute risk estimates as well as rate ratios between
different types of hormonal contraception.
Among the limitations of our study were the lack of
two potential confounders; family predisposition and
body mass index. When oral contraceptives contain-
ing desogestrel or gestodene were introduced in the
late 1980s they were considered safer than the older
types of oral contraceptives. Therefore, women with
a family predisposition for venous thromboembolism
were preferentially prescribed these new pills.
18 How-
ever,afternewstudieswerepublishedinthe1990sthis
preferential prescribing stopped and was not apparent
during 1994-8.
12
Being overweight predisposes to venous throm-
boembolism. If some oral contraceptives are preferen-
tially prescribed to women with an increased body
mass index, then the risk of these oral contraceptives
could be overestimated. However, when we carried
out the previous study on venous thromboembolism
during 1994-8 we had information on body mass
index and family predisposition.
12 Controlling for
these two potential confounders did not change the
risk estimates of venous thromboembolism as a result
of a weak association between body mass index and
family predisposition on the one hand and different
types of oral contraceptives on the other.
When the new oral contraceptive containing dros-
pirenone was introduced in Denmark in 2001, it was
not considered as safer than the older pills. Therefore
preferential prescribing of this pill to women at
increased risk of venous thromboembolism is not
expected. This was confirmed in a surveillance study,
in which the average body mass index among users of
oral contraceptives containing drospirenone was 22.9
and among users of oral contraceptives containing
levonorgestrel was 22.0, and the percentage with a
body mass index of 30 or more was, respectively,
8.2% and 5.3%.
13 In our study we were able to investi-
gatetheproportionofwomentakingothermedication
in the different subgroups of users of oral contracep-
tives. We found the same or lower prevalence in
users of oral contraceptives containing drospirenone
compared with oral contraceptives containing levo-
norgestrel, suggesting the same baseline health status.
In conclusion we have empirical data suggesting that
biasasaresultoffailingtocontrolforbodymassindex
and family predisposition was small, if present at all.
Another limitation was that the registry approach
did not permit us to evaluate the validity of each
included diagnosis of venous thromboembolism.
They were identified as the final discharge diagnosis
as reported to the National Registry of Patients. The
inclusion of about 10% uncertain diagnoses may have
biased our results, however, only if the misclassifica-
tion was differential, implying fewer or more women
with an uncertain diagnosis among current users of
oral contraceptives compared with non-users. In this
study the slightly lower risk estimates among current
users of oral contraceptives compared with our pre-
vious study in which these uncertain cases were
excluded
12mightsuggestfewerusersoforalcontracep-
tives among women with an uncertain diagnosis than
amongthosewithavalidatedandconfirmeddiagnosis.
Thereductioninoestrogendoseoforalcontraceptives
through the study period, however, could also have
contributed to the reduced risk estimates.
Finally, registry data do not include information
about lifestyle such as being sedentary, long distance
flights,andlimitedmobilityathome.Wethereforehad
noopportunitytoexploretheinteractionbetweensuch
conditions and use of hormonal contraception.
Clinical implications
For women of normal weight and without known
genetic predispositions, we recommend a low dose
combined pill as first choice for contraception. For
women genetically predisposed to venous thrombosis
who still want hormonal contraception, however, a
progestogen only pill or hormone releasing intra-
uterine device seemsto bethe appropriatefirst choice.
Before firm general clinical recommendations on
type of progestogen can be made we need data on the
effect of drospirenone on arterial end points. For
women with an increased body mass index; however,
alowdosecombinedpillwithlevonorgestrelshouldbe
firstchoice.Iftheriskofarterialdiseasesisthesamefor
the new progestogens as for levonorgestrel then
according to our figures about 7400 women should
changefromthenewerproductstooralcontraceptives
containing levonorgestrel to prevent one case of
venous thrombosis.
WHAT IS ALREADY KNOWN ON THIS TOPIC
Previous studies have shown an increased risk of venous thrombosis with use of combined
oral contraceptives and a higher risk with use of combined pills containing the progestogens
desogestrel or gestodene than containing levonorgestrel
WHAT THIS STUDY ADDS
The risk of venous thrombosis in users of combined oral contraceptives decreases with
decreasing dose of oestrogen
The risk of venous thrombosis from pills containing drospirenone corresponds to those
containing desogestrel or gestodene and is higher than with levonorgestrel
Progestogen only pills and hormone releasing intrauterine devices did not confer any
increased risk of venous thrombosis
The absolute risk of venous thrombosis with use of any types of combined oral
contraceptives in young women is less than one in 1000 user years
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